Get started
Author

María Casanova

Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
2018 · Mohamad Mohty, Evangelos Terpos, et al. · Clinical Lymphoma Myeloma & Leukemia · 84
Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial
2022 · Eva Giné, Fátima de la Cruz, et al. · Journal of Clinical Oncology · 65
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
2022 · Rosalinda Termini, David Žihala, et al. · Clinical Cancer Research · 55
PDF
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance–Like Phenotype in Patients With Monoclonal Gammopathies
2023 · Leire Burgos, Luis-Esteban Tamariz-Amador, et al. · Journal of Clinical Oncology · 34
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
2021 · Daniel Alameda, Ibai Goicoechea, et al. · Blood · 30
PDF
Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial
2021 · Noemi Puig, Miguel T. Hernández, et al. · Blood Cancer Journal · 28
Paraneoplastic pruritus presenting with Hodgkin’s lymphoma: a case report
2014 · Jose Javier Arenas Villafranca, Marga Garrido Siles, et al. · Journal of Medical Case Reports · 27
PDF
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
2018 · Noemi Puig, Bruno Paiva, et al. · Leukemia · 23
Minimally Invasive Assessment of Peripheral Residual Disease During Maintenance or Observation in Transplant-Eligible Patients With Multiple Myeloma
2024 · Marta Lasa, Laura Notarfranchi, et al. · Journal of Clinical Oncology · 20
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
2020 · Isabel Cuenca, Daniel Alameda, et al. · Leukemia · 17
PDF
Randomized Phase 2 Study of Weekly Carfilzomib 70 Mg/m2 and Dexamethasone Plus/Minus Cyclophosphamide in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients (GEM-KyCyDex)
2020 · Maria-Victoria Mateos, Enrique M. Ocio, et al. · Blood · 15
A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma
2015 · Antonio Rueda, Ramón García-Sanz, et al. · Acta Oncologica · 15
PDF
Pralatrexate, a new hope for aggressive T-cell lymphomas?
2009 · Antonio Rueda, María Casanova, et al. · Clinical & Translational Oncology · 13
Role of vascular endothelial growth factor C in classical Hodgkin lymphoma
2014 · Antonio Rueda, David Olmos, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 12
Has the time to come leave the “watch-and-wait” strategy in newly diagnosed asymptomatic follicular lymphoma patients?
2012 · Antonio Rueda, María Casanova, et al. · BMC Cancer · 10
PDF
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry
2024 · David F. Moreno, Cristina Jiménez, et al. · HemaSphere · 8
PDF
Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level
2023 · Ramón García-Sanz, María García-Álvarez, et al. · Disease Models & Mechanisms · 8
PDF
Determination of the Value Contribution of Belantamab Mafodotin (Belamaf; BLENREP®) for the Treatment of Triple-Class Refractory Multiple Myeloma in Spain through Reflective Multi-Criteria Decision Analysis
2021 · María Casanova, María Victoria Mateos, et al. · Economía de la Salud · 7
PDF
T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
2022 · Anna Sureda-Balari, M. José Terol, et al. · HemaSphere · 5
Efficacy and Safety of Ibrutinib in Combination with Rituximab As Frontline Treatment for Indolent Clinical Forms of Mantle Cell Lymphoma (MCL): Preliminary Results of Geltamo IMCL-2015 Phase II Trial
2019 · Eva Gine, Maria de Fatima De La Cruz, et al. · Blood · 5
A phase Ib/II trial combining brentuximab vedotin with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone ( BrEPEM ) for older patients with untreated classical Hodgkin lymphoma: A multicentre GELTAMO trial
2025 · Cecilia Carpio, Fátima de la Cruz‐Vicente, et al. · British Journal of Haematology · 4
Randomized Trial of Lenalidomide and Dexamethasone Versus Clarythromycin, Lenalidomide and Dexamethasone As First Line Treatment in Patients with Multiple Myeloma Not Candidates for Autologous Stem Cell Transplantation: Results of the GEM-Claridex Clinical Trial
2019 · Noemi Puig, Miguel T Hernández, et al. · Blood · 4
Chronic Clonal Proliferative Disease of Gamma-Delta (γδ) T-cells in a Patient with Rheumatoid Arthritis and Neutropenia: Lack of the Morphology and the Immunophenotype of Large Granular Lymphocytes
2004 · I Pérez Sánchez, J López Longo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4
Five‐year Update of the First‐line Imcl‐2015 Geltamo Study. Prolonged Molecular and Clinical Responses Were Observed After Mrd‐driven Ibrutinib Discontinuation
2023 · E. Giné, A. Medina‐Herrera, et al. · Hematological Oncology · 2
PDF
Definition and Clinical Significance of the MGUS-like Phenotype: A Study in 5,114 Patients (Pts) with Monoclonal Gammopathies
2021 · Leire Burgos, Luis Esteban Tamariz-Amador, et al. · Blood · 2
Works count: 89
Citation count: 505
H-index: 13
I10-index: 15
Year
Topic
Type